Literature DB >> 28374901

The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease.

Philip G Ferstl1,2, Natalie Filmann3, Christian Brandt2,4, Stefan Zeuzem1,2, Michael Hogardt2,4, Volkhard A J Kempf2,4, Mona Müller1, Oliver Waidmann1,2, Claudia Reinheimer2,4.   

Abstract

BACKGROUND & AIMS: Infections with multidrug-resistant gram-negative bacteria are significantly impairing the prognosis of patients with liver disease. In particular, carbapenem resistance further narrows therapeutic options. This study investigates the impact of carbapenem-resistant gram-negative bacteria on the outcome of patients with liver disease and cirrhosis.
METHODS: Between January 2011 and July 2015, 132 patients treated at the tertiary liver transplant centre at University Hospital Frankfurt, Germany, were tested positive for carbapenem-resistant gram-negative bacteria and retrospectively analysed in this study. Risk factors for fatal outcome were evaluated using multivariate regression analysis. Competing-risk analysis was performed on patients tested positive for Enterobacteriaceae or non-fermenting species, for example, Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia. Subgroup analysis of cirrhotic patients was performed on a matched cohort of cirrhotic patients, comparable model for end-stage liver disease and tested negative for carbapenem-resistant gram-negative bacteria.
RESULTS: 97 (73.5%) and 35 (26.5%) patients were infected or colonised with carbapenem-resistant gram-negative bacteria respectively. Within the observation period, 61/132 (46.2%) patients died, with sepsis being the leading cause (38/61, 62.3%). Decompensated liver disease, sepsis and admission to intensive care unit were independent risk factors for fatal outcome. Lethal sepsis in patients positive for non-fermenting bacteria was significantly more frequent than in those positive for Enterobacteriaceae, independently from liver function. Subgroup analysis of cirrhotic patients showed that sepsis (54.9% vs 13%) and lethal sepsis were significantly more frequent after detection of carbapenem-resistant gram-negative bacteria, independently from localisation of pathogen detection.
CONCLUSIONS: Patients with advanced liver disease are prone to fatal infections caused by carbapenem-resistant gram-negative bacteria.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  carbapenem resistance; cirrhosis; liver disease; multidrug-resistant organisms; sepsis

Mesh:

Substances:

Year:  2017        PMID: 28374901     DOI: 10.1111/liv.13438

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

1.  Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant Enterobacterales.

Authors:  Weili Wang; Rongrong Wang; Yuntao Zhang; Lei Zeng; Haisen Kong; Xueli Bai; Wei Zhang; Tingbo Liang
Journal:  Infect Drug Resist       Date:  2022-06-25       Impact factor: 4.177

2.  Noninvasive screening identifies patients at risk for spontaneous bacterial peritonitis caused by multidrug-resistant organisms.

Authors:  Philip G Ferstl; Mona Müller; Natalie Filmann; Michael Hogardt; Volkhard Aj Kempf; Thomas A Wichelhaus; Christian M Lange; Johannes Vermehren; Stefan Zeuzem; Claudia Reinheimer; Oliver Waidmann
Journal:  Infect Drug Resist       Date:  2018-11-02       Impact factor: 4.003

3.  Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates.

Authors:  Philip G Ferstl; Natalie Filmann; Eva-Maria Heilgenthal; Andreas A Schnitzbauer; Wolf O Bechstein; Volkhard A J Kempf; David Villinger; Tilman G Schultze; Michael Hogardt; Christoph Stephan; Haitham Mutlak; Nina Weiler; Marcus M Mücke; Jonel Trebicka; Stefan Zeuzem; Oliver Waidmann; Martin-Walter Welker
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

4.  Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma.

Authors:  Vera Himmelsbach; Mate Knabe; Phillip G Ferstl; Kai-Henrik Peiffer; Jan A Stratmann; Thomas A Wichelhaus; Michael Hogardt; Volkhard A J Kempf; Stefan Zeuzem; Oliver Waidmann; Fabian Finkelmeier; Olivier Ballo
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-20       Impact factor: 4.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.